Johns Hopkins University will use Orgenesis’ point-of-care processing technology for cell and gene therapy research in a collaboration announced this week. The US research University has licensed access to Orgenesis’s ‘point-of-care’ (PoC) platform which – as the name suggests – is used to develop and process cell therapies in the clinic Orgenesis CEO Vered Caplan said, “Our POCare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed…

Sanofi Pasteur has joined Johnson & Johnson as the second firm to team up with BARDA to take on coronavirus (COVID-19). According to a statement, Sanofi Pasteur will use recombinant DNA tech to make a vaccine against the virus that has sickened tens of thousands and resulted in hundreds of deaths since it emerged in China last year. The plan is to use the Sanofi technology to reverse engineer proteins isolated from the virus to produce DNA sequences. These sequences…

Concerns about CAR-T safety continue to be a challenge for the sector according to Bristol-Myers Squibb, which outlined plans to address such “headwinds” during a Q4 call. Bristol Myers Squibb (BMS) spoke about the chimeric antigen receptor (CAR) T-cells sector last week, explaining while the market for such therapies is expanding, growth rates are not as fast as they could be. Nadim Ahmed, president of BMS hematology department, told analysts: “Clearly, there have been some headwinds in the [CAR-T] marketplace and…